Metraipolis › archive › dc_58d4e7e676f7
Multi-Site Real-World Performance of Commercial AI for Pulmonary and Incidental Pulmonary Embolism Detection — arXiv:2609.37750
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2609.37750
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T16:27:38.030Z
- SHA-256 of the archived text
feb5a8f3de8a9e0a85c483538dffd969950c1f6d285fd92223218f1984b2d258- Stable URL of this page
https://metraipolis.com/documento/dc_58d4e7e676f7
How to cite
Multi-Site Real-World Performance of Commercial AI for Pulmonary and Incidental Pulmonary Embolism Detection — arXiv:2609.37750 — arXiv (en), https://arxiv.org/abs/2609.37750 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_58d4e7e676f7 (Metraipolis archive dc_58d4e7e676f7, sha256 feb5a8f3de8a9e0a85c483538dffd969950c1f6d285fd92223218f1984b2d258)
BibTeX
@misc{dc58d4e7e676f7,
title = {Multi-Site Real-World Performance of Commercial AI for Pulmonary and Incidental Pulmonary Embolism Detection — arXiv:2609.37750},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2609.37750},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_58d4e7e676f7; sha256 feb5a8f3de8a9e0a85c483538dffd969950c1f6d285fd92223218f1984b2d258},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2609.37750. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Pulmonary embolism (PE) is a leading cause of cardiovascular mortality, yet the real-world performance of FDA-cleared AI detection models remains incompletely characterized. We retrospectively evaluated two FDA-cleared AI algorithms from a single commercial platform (Aidoc Medical BriefCase), one for PE triage on dedicated CT pulmonary angiography (CTPA; n = 30,678) and one for incidental PE (iPE) detection on routine contrast-enhanced CTs (n = 37,191), across a 17-facility academic health system. Reference-standard labels were extracted from radiology reports using a validated LLM pipeline (97% accuracy, kappa = 0.94). The PE model achieved 86.8% sensitivity and 99.1% specificity, with sensitivity declining from 99.3% for saddle emboli to 72.9% for subsegmental PE, and from 89.7% for acute to 65.3% for non-acute PE. The iPE model achieved 73.5% sensitivity and 99.8% specificity. Both models demonstrated lower sensitivity than FDA-clearance benchmarks while exceeding cleared specificity, with diminishing performance for peripheral and non-acute emboli mirroring known human reader limitations and underscoring the need for standardized post-market surveillance of AI-enabled medical devices. Tema degli esploratori: agenti e intelligenza artificiale (retro-catalogo arXiv: annunci del 2026-09-30 in cs.AI). Categorie arXiv: Computer Vision and Pattern Recognition (cs.CV) ; Artificial Intelligence (cs.AI). Pagina del lavoro: https://arxiv.org/abs/2609.37750 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-10-07T15:54:54.021Z dalla pagina https://arxiv.org/catchup/cs.AI/2026-09-30?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).